Skip to content

Evaluation of efficacy of Polyherbal Formulation in the Management of Melasma.

Evaluation of efficacy and safety of Unani formulation in the management of Kalf (Melasma): A Randomized Controlled Study. - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094063
Enrollment
51
Registered
2025-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Zimad (Topical Unani Formulation): It will be subjected to same Zimad Alsi + Vinegar topical Unani formulation for local application to the affected area for 30 minutes once daily for

Sponsors

Hakim Syed Ziaul Hasan Government Unani Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of all sexes between 18-50 years Clinically diagnosed patient of Melasma Female of reproductive age group agree to use acceptable form of birth control during study (except IUCD and hormonal contraception) Patient willing to sign the informed consent and to complete the study

Exclusion criteria

Exclusion criteria: Pregnant and lactating females Females using OCP (oral contraceptive pills) IUCD and hormonal contraception Patient having other skin diseases like acne dermatitis urticaria dermatophytosis Patients who have a known history or clinically relevant allergy in particular to any component of study medication Having systemic disorders such as hepatic and renal insufficiency endocrine disorders malignant or premalignant lesions immunodeficiency diseases neurological and cardiac disorders Patient consuming alcohol or drug abuse Patient have taken topical or systemic treatment of melasma for last one month Patient receive any cosmetic procedure such as chemical peel laser ablation FRT or dermabrasion for last 3 months Not willing to sign informed consent

Design outcomes

Primary

MeasureTime frame
1.Melasma severity index 2.Photography 3.Safety evaluationTimepoint: 1.on day 0, 21, 42 2.on day 0, 42 3.on day 0, 42

Secondary

MeasureTime frame
MELASQOL (Melasma Quality of Life Scale)Timepoint: on Day 0, 42

Countries

India

Contacts

Public ContactYougshi Ilahi

Hakim Syed Ziaul Hasan Government Unani Medical College and Hospital

mohddr@gmail.com7828550209

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026